Sanford C. Bernstein Forecasts Strong Price Appreciation for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price objective upped by research analysts at Sanford C. Bernstein from $90.00 to $94.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Sanford C. Bernstein’s price objective would suggest a potential upside of 53.82% from the stock’s current price.

A number of other analysts have also recently weighed in on the stock. Wedbush restated an “outperform” rating and issued a $94.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday, October 28th. Wells Fargo & Company upped their price target on BioMarin Pharmaceutical from $70.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Royal Bank Of Canada restated a “sector perform” rating and set a $66.00 target price on shares of BioMarin Pharmaceutical in a research note on Tuesday, October 28th. Leerink Partners cut BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $82.00 to $60.00 in a research note on Wednesday, December 3rd. Finally, Canaccord Genuity Group upgraded BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and boosted their price target for the stock from $84.00 to $98.00 in a research note on Tuesday, January 20th. Fifteen investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $87.71.

BioMarin Pharmaceutical Trading Down 0.5%

Shares of NASDAQ BMRN opened at $61.11 on Wednesday. BioMarin Pharmaceutical has a 1-year low of $50.76 and a 1-year high of $73.51. The business has a fifty day moving average price of $58.90 and a 200 day moving average price of $56.15. The stock has a market capitalization of $11.74 billion, a P/E ratio of 34.33, a price-to-earnings-growth ratio of 0.52 and a beta of 0.26. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.21 and a quick ratio of 3.10.

Insider Buying and Selling at BioMarin Pharmaceutical

In other news, EVP Gregory R. Friberg sold 6,326 shares of the firm’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $60.38, for a total value of $381,963.88. Following the completion of the transaction, the executive vice president directly owned 37,578 shares in the company, valued at $2,268,959.64. This trade represents a 14.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of large investors have recently bought and sold shares of the company. Dodge & Cox raised its position in BioMarin Pharmaceutical by 1.0% during the 2nd quarter. Dodge & Cox now owns 15,108,310 shares of the biotechnology company’s stock worth $830,504,000 after buying an additional 153,070 shares during the last quarter. Viking Global Investors LP increased its stake in shares of BioMarin Pharmaceutical by 13.8% in the second quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock worth $675,505,000 after acquiring an additional 1,488,552 shares during the period. Norges Bank purchased a new position in shares of BioMarin Pharmaceutical during the fourth quarter worth $447,572,000. AQR Capital Management LLC raised its holdings in shares of BioMarin Pharmaceutical by 12.7% during the fourth quarter. AQR Capital Management LLC now owns 6,686,916 shares of the biotechnology company’s stock worth $395,197,000 after purchasing an additional 754,807 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in BioMarin Pharmaceutical by 3.7% during the fourth quarter. Geode Capital Management LLC now owns 3,674,089 shares of the biotechnology company’s stock valued at $218,395,000 after purchasing an additional 131,969 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Wells Fargo called BMRN an attractive buy ahead of the Transcon‑CNP PDUFA, signaling investor interest around the upcoming regulatory decision. Wells Fargo Buy Note
• Positive Sentiment: Sanford C. Bernstein raised its price target from $90 to $94 and kept an outperform rating — a direct positive signal from a major sell‑side shop. Bernstein PT Raise (Benzinga)
• Positive Sentiment: Analysis pieces argue that recent share rebound and DCF assumptions may still imply upside for BMRN, supporting a constructive view for longer‑term investors. Pricing / DCF Upside Analysis
• Neutral Sentiment: Analysts broadly revised forecasts after Q4 results; the coverage is mixed and driving headline activity but not a uniform consensus. Analyst Revisions (Benzinga)
• Neutral Sentiment: BioMarin’s Q4 earnings call highlights were released; investors will parse guidance and R&D updates for implications on cash runway and upcoming catalysts. Q4 Earnings Call Highlights
• Neutral Sentiment: Short‑interest reports flagged a “large increase,” but the filings in the feed show inconsistent/zero values (NaN/0), making the short‑interest signal unreliable for now; not a clear driver.
• Negative Sentiment: HC Wainwright cut its price target to $55 and moved to a neutral rating, a downgrade that reduces near‑term sentiment given the lower target relative to recent levels. HC Wainwright PT Cut (Benzinga)
• Neutral Sentiment: Guggenheim trimmed its target from $106 to $86 but kept a buy rating; Oppenheimer also lowered its target to $95 — mixed signals that compress consensus and increase short‑term volatility. Guggenheim / Oppenheimer Coverage (Benzinga / AmericanBankingNews) Read More.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.